Form 4: Ideaya Biosciences Executive Acquires 15,000 Stock Options

Stuart Dorman, Chief Commercial Officer of Ideaya Biosciences, acquired 15,000 stock options at an exercise price of $20.24 on February 27, 2025.

Summary

• On February 27, 2025, Stuart Dorman, the Chief Commercial Officer of Ideaya Biosciences, Inc. (IDYA), acquired 15,000 stock options.
• The exercise price for these options is $20.24.
• The options vest over a four-year period, starting January 1, 2025, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
• The expiration date for these options is February 26, 2035.
• Following the transaction, Dorman directly owns 15,000 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral event, simply a disclosure of stock option grants to an executive. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company executives.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates